German China

Novel Methods of Analysis Artificial Intelligence Tool Successfully Predicts Fatal Heart Rhythm

Source: University Hospitals of Leicester NHS Trus 2 min Reading Time

Researchers from the University of Leicester developed an AI tool that has shown an 80 % accuracy rate in predicting lethal heart rhythm conditions. This tool, VA-ResNet-50, analyzed Holter ECGs from 270 adults, identifying those at risk of ventricular arrhythmias — a rapid heart condition that can lead to sudden death.

Ventricular arrhythmia (VA) is a heart rhythm disturbance originating from the bottom chambers.(Source:  free licensed /  Pixabay)
Ventricular arrhythmia (VA) is a heart rhythm disturbance originating from the bottom chambers.
(Source: free licensed / Pixabay)

In a Leicester study that looked at whether artificial intelligence (AI) can be used to predict whether a person was at risk of a lethal heart rhythm, an AI tool correctly identified the condition 80 per cent of the time. The findings of the study, led by Dr Joseph Barker working with Professor Andre Ng, Professor of Cardiac Electrophysiology and Head of Department of Cardiovascular Sciences at the University of Leicester and Consultant Cardiologist at the University Hospitals of Leicester NHS Trust, have been published in the European Heart Journal – Digital Health.

Ventricular arrhythmia (VA) is a heart rhythm disturbance originating from the bottom chambers (ventricles) where the heart beats so fast that blood pressure drops which can rapidly lead to loss of consciousness and sudden death if not treated immediately.

NIHR Academic Clinical Fellow Dr Joseph Barker co-ordinated the multicentre study at the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre,  and co-developed an AI tool with Dr Xin Li, Lecturer in Biomedical Engineering, School of Engineering. The tool examined Holter electrocardiograms (ECGs) of 270 adults taken during their normal daily routine at home. These adults had the Holter ECGs taken as part of their NHS care between 2014 and 2022. Outcomes for these patients were known, and 159 had sadly experienced lethal ventricular arrhythmias, on average 1.6 years following the ECG.

The AI tool, VA-ResNet-50, was used to retrospectively examine ‘normal for patient’ heart rhythms to see if their heart was capable of the lethal arrythmias. Professor Ng said: “Current clinical guidelines that help us to decide which patients are most at risk of going on to experience ventricular arrhythmia, and who would most benefit from the life-saving treatment with an implantable cardioverter defibrillator are insufficiently accurate, leading to a significant number of deaths from the condition. Ventricular arrhythmia is rare relative to the population it can affect, and in this study we collated the largest Holter ECG dataset associated with longer term VA outcomes.”

The researchers found the AI tool performed well compared with current medical guidelines, and correctly predicted which patient’s heart was capable of ventricular arrhythmia in four out of every five cases. If the tool said a person was at risk, the risk of lethal event was three times higher than normal adults. These findings suggest that using artificial intelligence to look at patients’ electrocardiograms while in normal cardiac rhythm offers a novel lens through which we can determine their risk, and suggest appropriate treatment; ultimately saving lives.

Professor Ng added: “This is important work, which wouldn’t have been possible without an exceptional team in Dr Barker and Dr Xin Li, and their belief and dedication to novel methods of analysis of historically disregarded data.”

Dr Barker’s work has been recognised with a van Geest Foundation Award and Heart Rhythm Society Scholarship and more research will be carried out to develop the work further.

Original Article: Artificial intelligence for ventricular arrhythmia capability using ambulatory electrocardiograms; European Heart Journal

(ID:49981649)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent